Leonardo S Lino-Silva1,2, Patricia Segales-Rojas3, Eduardo Aguilar-Cruz4, Rosa A Salcedo-Hernández5, César Zepeda-Najar6. 1. Surgical Pathology, Instituto Nacional de Cancerología, Mexico City, Mexico. saul.lino.sil@gmail.com. 2. Anatomic Pathology, Gastrointestinal Pathology Division, Instituto Nacional de Cancerología de México (Mexico's National Cancer Institute), Av. San Fernando # 22, Sección XVI, Tlalpan, 14080, Mexico City, Mexico. saul.lino.sil@gmail.com. 3. Surgical Pathology, Instituto Nacional de Cancerología, Mexico City, Mexico. 4. Anatomic Pathology, Gastrointestinal Pathology Division, Instituto Nacional de Cancerología de México (Mexico's National Cancer Institute), Av. San Fernando # 22, Sección XVI, Tlalpan, 14080, Mexico City, Mexico. 5. Surgical Oncology, Instituto Nacional de Cancerología, Mexico City, Mexico. 6. Surgical Oncology, Hospital Ángeles Tijuana, Tijuana, Baja California Norte, Mexico.
Abstract
PURPOSE: Gastrointestinal stromal tumors (GIST) have the potential to recur and metastasize. Several prognostic schemes have been developed, mostly based on the mitotic count, diameter, and tumor site. However, these systems are not precise enough. The research question was whether the tumor size determined by volumetry allows a better risk stratification than the traditional system, and our aim was to determine the value of tumor volumetry, a feasible and simple parameter, in the recurrence of GIST. METHODS: Seventy-four cases of GIST were studied. The cases presented with non-metastatic disease, which were resected and did not receive imatinib. We compared the clinico-pathologic features of the cases with recurrence against those with non-recurrence and compared the tumor volumetry against the classification system based on tumor size and mitosis. RESULTS: The median age was 58 years (range: 25 to 91 years). Half of the cases were presented in the stomach. The tumor size had a median of 8 cm (range of 1-30 cm). The median mitosis count for 50 HPF was 4 (range 0-92). During the period of study, 16 (21.6%) patients suffered recurrence. The significant differences were that patients with recurrence accounted for more deaths and the follow-up period was larger. The area under the curve (AUC) of the volumetry classification was superior to the AUC of the classification system based on tumor size and mitosis (NIH-criteria) (p = .05). CONCLUSION: Tumor volumetry calculated in the surgical specimen and/or pre-operative tomography was superior to the NIH consensus in stratifying the risk of recurrence in GIST.
PURPOSE:Gastrointestinal stromal tumors (GIST) have the potential to recur and metastasize. Several prognostic schemes have been developed, mostly based on the mitotic count, diameter, and tumor site. However, these systems are not precise enough. The research question was whether the tumor size determined by volumetry allows a better risk stratification than the traditional system, and our aim was to determine the value of tumor volumetry, a feasible and simple parameter, in the recurrence of GIST. METHODS: Seventy-four cases of GIST were studied. The cases presented with non-metastatic disease, which were resected and did not receive imatinib. We compared the clinico-pathologic features of the cases with recurrence against those with non-recurrence and compared the tumor volumetry against the classification system based on tumor size and mitosis. RESULTS: The median age was 58 years (range: 25 to 91 years). Half of the cases were presented in the stomach. The tumor size had a median of 8 cm (range of 1-30 cm). The median mitosis count for 50 HPF was 4 (range 0-92). During the period of study, 16 (21.6%) patients suffered recurrence. The significant differences were that patients with recurrence accounted for more deaths and the follow-up period was larger. The area under the curve (AUC) of the volumetry classification was superior to the AUC of the classification system based on tumor size and mitosis (NIH-criteria) (p = .05). CONCLUSION:Tumor volumetry calculated in the surgical specimen and/or pre-operative tomography was superior to the NIH consensus in stratifying the risk of recurrence in GIST.
Authors: Brian P Rubin; Charles D Blanke; George D Demetri; Ronald P Dematteo; Christopher D M Fletcher; John R Goldblum; Jerzy Lasota; Alexander Lazar; Robert G Maki; Markku Miettinen; Amy Noffsinger; Mary Kay Washington; Thomas Krausz Journal: Arch Pathol Lab Med Date: 2010-02 Impact factor: 5.534
Authors: P Rutkowski; E Bylina; A Wozniak; Z I Nowecki; C Osuch; M Matlok; T Switaj; W Michej; M Wroński; S Głuszek; J Kroc; A Nasierowska-Guttmejer; H Joensuu Journal: Eur J Surg Oncol Date: 2011-07-07 Impact factor: 4.424
Authors: Javier Martín; Andrés Poveda; Antonio Llombart-Bosch; Rafael Ramos; José A López-Guerrero; Javier García del Muro; Joan Maurel; Silvia Calabuig; Antonio Gutierrez; José L González de Sande; Javier Martínez; Ana De Juan; Nuria Laínez; Ferrán Losa; Valentín Alija; Pilar Escudero; Antonio Casado; Paula García; Pilar García; Remei Blanco; José M Buesa Journal: J Clin Oncol Date: 2005-09-01 Impact factor: 44.544
Authors: Christopher D M Fletcher; Jules J Berman; Christopher Corless; Fred Gorstein; Jerzy Lasota; B Jack Longley; Markku Miettinen; Timothy J O'Leary; Helen Remotti; Brian P Rubin; Barry Shmookler; Leslie H Sobin; Sharon W Weiss Journal: Hum Pathol Date: 2002-05 Impact factor: 3.466
Authors: N Schramm; E Englhart; M Schlemmer; M Hittinger; C Übleis; C R Becker; M F Reiser; F Berger Journal: Eur J Radiol Date: 2013-03-19 Impact factor: 3.528